SCHEMBL1574488

SCHEMBL1574488

Cc1ccc(NC(=O)N2CC(N(C(C)C)C(C)C)C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.54
NPC1 O15118 4/20 0.54
TAS1R3 Q7RTX0 2/20 0.51
TAS1R1 Q7RTX1 2/20 0.51
TAS1R2 Q8TE23 2/20 0.51
NAMPT P43490 1/20 0.51
GRIN2B Q13224 4/20 0.50
TSHR P16473 2/20 0.50
MAPT P10636 2/20 0.47
PAX8 Q06710 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
KMT2A Q03164 1/20 0.46
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KDM4E B2RXH2 1/20 0.46
FAAH O00519 1/20 0.45
GFER P55789 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574445 0.87 NPC1 (0.57) RAB9ANPC1MAPTSMN1; SMN2TP53
SCHEMBL1574936 0.87 KMT2A (0.52) RAB9ANPC1GRIN2BMAPTSMN1; SMN2
SCHEMBL1574458 0.87 TAS1R3 (0.50) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL1574702 0.87 GRIN2B (0.52) RAB9ANPC1GRIN2BTSHRMAPT
SCHEMBL1575268 0.86 MAPT (0.45) RAB9ANPC1TSHRMAPTLMNA
SCHEMBL1575254 0.85 NPC1 (0.57) RAB9ANPC1TSHRMAPTSMN1; SMN2
SCHEMBL1574353 0.85 MAPT (0.61) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL1573328 0.84 ALDH1A1 (0.59) RAB9AGRIN2BMAPTSMN1; SMN2LMNA
SCHEMBL1574694 0.84 RAB9A (0.58) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL1575273 0.82 NPC1 (0.50) RAB9ANPC1TAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB RAB9A 898/4885NPC1 413/4885TAS1R3 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.